4//SEC Filing
SIRNA THERAPEUTICS INC 4
Accession 0001140484-05-000014
CIK 0000892112operating
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 4:51 PM ET
Size
14.4 KB
Accession
0001140484-05-000014
Insider Transaction Report
Form 4
OXFORD BIOSCIENCE PARTNERS IV LP
10% Owner
Transactions
- Purchase
Common
2005-07-06$1.60/sh+1,237,582$1,980,131→ 5,807,127 total - Purchase
Warrants (right to buy)
2005-07-06+445,529→ 445,529 totalExercise: $1.92→ Common Stock (445,529 underlying) - Purchase
Common
2005-07-06$1.60/sh+12,418$19,869→ 58,267 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrants (right to buy)
2005-07-06+4,470→ 4,470 total(indirect: By mRNA Fund II L.P.)Exercise: $1.92→ Common Stock (4,470 underlying)
MRNA FUND II LP
10% Owner
Transactions
- Purchase
Warrants (right to buy)
2005-07-06+445,529→ 445,529 totalExercise: $1.92→ Common Stock (445,529 underlying) - Purchase
Common
2005-07-06$1.60/sh+1,237,582$1,980,131→ 5,807,127 total - Purchase
Common
2005-07-06$1.60/sh+12,418$19,869→ 58,267 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrants (right to buy)
2005-07-06+4,470→ 4,470 total(indirect: By mRNA Fund II L.P.)Exercise: $1.92→ Common Stock (4,470 underlying)
Footnotes (4)
- [F1]Securities Oxford Bioscience Partners IV L.P. ("Oxford IV") is irrevocably committed to acquire. By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA Fund II L.P. ("mRNA") may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
- [F2]Securities mRNA is irrevocably committed to acquire. By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
- [F3]In the event that the shares of the Company's Common Stock are (i) terminated from registration under the Securities Act of 1933, as amended during the time in which the Company remains obligated to keep the registration statement (to be filed with respect to the shares issued in a private placement pursuant to a stock purchase agreement dated as of July 6, 2005) current, effective and free from any material misstatement or omission to state a material fact or (ii) delisted from the Nasdaq National Market, the Warrant Price then in effect at the time of such deregistration or delisting shall be reduced to $1.67 per share.
- [F4]The warrant is exercisable from approximately January 2006 to the fifth anniversary of the date of grant.
Documents
Issuer
SIRNA THERAPEUTICS INC
CIK 0000892112
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000892112
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 4:51 PM ET
- Size
- 14.4 KB